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Background: Postoperative urinary retention (PO-UR) is an acute and painful inability to void after
surgery that can lead to complications and delayed hospital discharge. Standard treatment with a urinary
catheter is associated with a risk of infection and can be distressing, undignified and uncomfortable. This
systematic review aimed to identify effective interventions for the prevention and treatment of PO-UR
that might be alternatives to urinary catheterization.
Methods: Electronic databases were searched from inception to September 2017. Randomized trials
of interventions for the prevention or treatment of PO-UR were eligible for inclusion. Studies were
assessed for risk of bias using the Cochrane (2.0) tool. Two reviewers were involved at all review stages.
Where possible, data were pooled using random-effects meta-analysis. The overall quality of the body
of evidence was rated using the GRADE approach.
Results: Some 48 studies involving 5644 participants were included. Most interventions were pharma-
cological strategies to prevent PO-UR. Based on GRADE, there was high-certainty evidence to support
replacing morphine in a regional anaesthetic regimen, using alpha-blockers (number needed to treat
to prevent one case of PO-UR (NNT) 5, 95 per cent c.i. 5 to 7), the antispasmodic drug drotaverine
(NNT 9, 7 to 30) and early postoperative mobilization (NNT 5, 4 to 8) for prevention, and employ-
ing hot packs or gauze soaked in warm water for treatment (NNT 2, 2 to 4). Very few studies reported
on secondary outcomes of pain, incidence of urinary tract infection or duration of hospital stay.
Conclusion: Promising interventions exist for PO-UR, but they need to be evaluated in randomized trials
investigating comparative clinical and cost effectiveness, and acceptability to patients.
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Introduction
Postoperative urinary retention (PO-UR) is frequently
regarded as a minor adverse side-effect of surgery, easily
resolved by catheterization. The condition can, how-
ever, be distressing. Patients may find catheterization
invasive, undignified and uncomfortable. Catheteriza-
tion also carries risks of urinary tract infection1, which
may lead to further complications such as infection
of a joint prosthesis2. Untreated, PO-UR can lead to
overdistension of the bladder with acute kidney injury
and detrusor muscle damage3. These events can result in
delayed hospital discharge4 and additional care following
hospital discharge.
Multiple perioperative predictors have been proposed
for the development of PO-UR, including age, sex, type
of anaesthesia and analgesia3,5. The varying standards
and definitions adopted by different studies, along with
the multifactorial aetiology of PO-UR, are reflected by
the wide-ranging reported incidence for this problem
of between 5⋅7 and 69 per cent6. Surgical populations
at high risk of developing PO-UR include joint arthro-
plasty (10⋅7–84 per cent), anorectal surgery (1–52 per
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cent), hernia repair (5⋅9–38 per cent)3 and gynaecological
surgery (4–15 per cent)7.
Interventions to prevent or treat PO-UR include phar-
macological (such as cholinergic agents, alpha-adrenergic
blockers), massage, acupuncture and warm compress
approaches. Interventions targeting anaesthesia and anal-
gesia represent a potential preventive strategy. A clinical
protocol of interventions effective in preventing PO-UR,
and treatment alternatives to catheterization, could lead to
improved postoperative morbidity, reduction in associated
complications, and improvements for patients with respect
to dignity, comfort and psychological wellbeing.
The aim of this systematic review was to provide an over-
all summary of the available trial evidence on interventions
to prevent or treat urinary retention after surgery.
Methods
This review followed Cochrane recommendations for con-
ducting systematic reviews8. The objectives, eligibility cri-
teria and review methods were prespecified in a protocol
registered with PROSPERO (CRD42016048765)9.
Study selection
RCTs investigating any intervention with the specific aim
of preventing or treating PO-UR in an adult surgical
population were included. Where the intervention was
aimed at preventing PO-UR, any adult surgical population
was included. Where an intervention was aimed at treat-
ing PO-UR, any adult surgical population experiencing
PO-UR according to the authors’ definition was included.
Populations with known pre-existing urinary problems,
such as benign prostatic obstruction, cancer of the blad-
der or prostate, or urinary incontinence, were excluded.
Studies had to report incidence of PO-UR, defined as uri-
nary retention with a postoperative onset requiring urgent
intervention, such as catheter insertion, recatheterization
(where catheter use was part of the treatment proto-
col), pharmacological or non-pharmacological treatment.
Catheter use was considered as a proxy measure of PO-UR
(if not stated explicitly that the catheter was inserted to treat
urinary retention). Outcomes defined as ‘postoperative
voiding dysfunction’, ‘voiding difficulties’ or based on a
postvoid residual urinary bladder volume alone were not
considered PO-UR.
Identification and selection of studies
The following electronic databases were searched from
inception to September 2017: MEDLINE (OVID) includ-
ing MEDLINE in process, Embase (OVID), Cochrane
Library (Wiley), Cumulative Index to Nursing and Allied
Health Literature (CINAHL) (EBSCO), Science Cita-
tion Index and Conference proceedings – Science (Web
of Science). The search strategies were developed specif-
ically for each database (MEDLINE example included
in Appendix S1, supporting information). Searches were
limited to studies in humans, but were not limited by lan-
guage, date or publication status.
Supplementary internet searches were undertaken to
identify grey literature, including ongoing and completed
clinical trials from the WHO International Clinical Trials
Registry (www.who.int/ictrp/en) andNational Institutes of
Health Clinical Trials (clinicaltrials.gov).
The review team included a public contributor with
personal experience of PO-UR and researchers from the
National Institute for Health Research Collaboration for
Leadership in Applied Health Research and Care West
(NIHR CLAHRCWest). Taking on the role of a reviewer,
the public contributor was actively involved in all aspects
of screening and data extraction. Titles and abstracts were
each screened independently by twomembers of the review
team. All references that did not meet the inclusion criteria
were excluded. Full-text papers for each of the remaining
references were obtained and examined independently in
detail by two reviewers. Discrepancies between reviewers
at each stage were resolved by discussion with a third
reviewer.
Data extraction and study appraisal
Data were extracted using a standard form developed
in Microsoft Access® 2010 (Microsoft, Redmond, Wash-
ington, USA) to include: eligibility criteria, study
characteristics, participant characteristics, interven-
tion, comparator, outcome definitions and outcome
data for incidence of PO-UR. Data were also extracted for:
rates of urinary tract infection (UTI), duration of hospital
stay, patient acceptability, adverse events (for example
mortality) and pain scores. Data extraction was performed
by one reviewer and checked by a second; disagreements
were resolved by discussion with a third reviewer. Where
PO-UR was reported at multiple time points, data for the
initial time point were extracted.
Included studies were assessed independently for risk
of bias by two reviewers, using the Cochrane Risk of
Bias tool (ROB 2.0)10,11. This includes assessment criteria
covering selection bias (random sequence generation and
allocation concealment), performance bias (participant
blinding), detection bias (blinding of outcome assessors),
attrition bias (incomplete outcome data) and reporting
bias (selective reporting).
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Fig. 1 PRISMA flow diagram for the review
Statistical analysis
Comparisons were grouped by aim (prevention, treatment),
intervention type (pharmacological, non-pharmacological)
and intervention category. For dichotomous data, an odds
ratio (OR) for each comparison with associated 95 per
cent confidence intervals was calculated. Continuous data
were analysed as the weighted mean difference (MD)
between groups and presented with associated 95 per
cent confidence intervals. Where there were two or more
studies in an intervention category, data were pooled using
random-effects meta-analysis. To avoid double-counting,
where multiple different interventions were compared
with the same control group, the control group was split
into two or more smaller groups of equal size before being
entered into the analysis. This approach permitted reten-
tion of as many relevant comparisons as possible8. If the
study compared multiple different doses of the same drug
with a control group, intervention groups were combined
and data were entered into the meta-analysis as a single
comparison. Heterogeneity within groups was investigated
using visual inspection of forest plots and quantified using
the I2 statistic12,13. Where it was considered inappropriate
to pool data, a narrative synthesis is provided.
The GRADE approach was used to rate the overall
quality of the body of evidence for risk of bias, publication
bias, imprecision, inconsistency and indirectness. GRADE
ratings of very low, low,moderate or high certaintymeasure
the overall quality of the evidence and reflect confidence in
the evidence for each effect estimate14.
Results
After removal of duplicate records, 6415 reports were iden-
tified of which 48 studies15–68 (5644 participants) were
included in the review (Fig. 1). Characteristics of included
studies are summarized in Table 1, with additional detail in
Tables S1–S4 (supporting information).
Description of included studies
The majority of included studies were conducted in surgi-
cal populations with a higher risk of developing PO-UR.
Ten studies included only men and seven included
only women. Of the 24 studies that included both men
and women, 56⋅6 per cent were men overall. Seven studies
did not report on the sex of included participants. Sample
size ranged from 30 to 496 (median 99). More studies
targeted prevention than considered treatment of PO-UR
(41 versus 7), and pharmacological interventions were
evaluated more commonly than non-pharmacological
measures. All studies used a definition of PO-UR that
involved some form of active treatment, most commonly
catheterization. In addition, some included a measure of
bladder volume or a palpable bladder.
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Table 1 Summary of trial characteristics (number of studies)
No. of arms Two arms (36), three arms (5), four
arms (7)
Countries USA (13), Korea (6), Iran (4), China (3),
Denmark (3), Israel (3), UK (2), Poland (2),
Turkey (2), Austria (1), Egypt (1), Finland
(1), France (1), Germany (1), Pakistan (1),
Sweden (1), Taiwan (1), Spain (1), n.r. (1)
Type of surgery Haemorrhoidectomy (7), anorectal (6),
hip or knee arthroplasty (5), inguinal
hernia (5), mixed surgical populations (5),
orthopaedic (5), urogynaecological (5),
knee arthroscopy (2), caesarean (1),
cataract (1), spinal surgery (2),
gastrointestinal (2), lower limb surgery
(1), n.r. (1)
Prevention of PO-UR*
Pharmacological (46) Anaesthesia (7), morphine avoidance (4),
morphine replacement (2), morphine
administration (1), NSAID suppository
(2), alpha-blocker (15), μ-opioid
antagonist (2), antispasmodic (1),
benzodiazepine (1), cholinergic (4)
Non-pharmacological (11) Fluids (3), mobilization (2), acupuncture
(1), external bladder stimulator (1),
preoperative ultrasound monitoring (1),
straight catheterization in recovery room
(1), postoperative anal packing (1)
Treatment of PO-UR*
Pharmacological (12) Alpha-blockers (4), cholinergic ±
benzodiazepines (4)
Non-pharmacological (5) Gauze soaked in warm water/hot pack
(3), caffeine (1), posterior tibial nerve
stimulation (1), moxibustion (2), infrared
radiation (1)
Secondary outcomes UTI (5), length of hospital stay (6), pain
(7)
*Some studies are included twice or more as they evaluated multiple
interventions. n.r., Not reported; PO-UR, postoperative urinary
retention; NSAID, non-steroidal anti-inflammatory drug; UTI, urinary
tract infection.
Of the 48 included trials, ten17,23,28,32,38,39,45,55–57,67,68
were considered to be at low risk of bias; eight of
these evaluated pharmacological interventions and
two evaluated non-pharmacological interventions.
Eleven18,22,25,29,30,35,40–43,54,60,66 were judged at high
risk of bias; these studies evaluated pharmacological (7
studies) and non-pharmacological (3) interventions for the
prevention of PO-UR, and a pharmacological interven-
tion (1 study) for the treatment of PO-UR. There were
27 studies15,16,19–21,24,26,27,31,33,34,36,37,44,46–53,58,59,61–65
rated as having some concerns; these studies evaluated
pharmacological (16 studies) and non-pharmacological
(5) interventions for the prevention of PO-UR, and
pharmacological (2) and non-pharmacological (4) inter-
ventions for treating PO-UR.
The main potential limitations of the included studies
were methods of randomization/concealment (35 trials)
or blinding of participants/carers (23). Fewer studies were
found to have concerns regarding missing data (6), fail-
ure to blind outcome assessor (8) and selective reporting
(8). Overall and domain-level assessments of risk of bias
for each trial are provided in Appendix S2 (supporting
information).
Pharmacological interventions for prevention
of postoperative urinary retention (Tables S5
and S6)
Morphine use in a regional anaesthetic regimen (9 trials,
530 participants) (Fig. 2)
Reducing exposure to morphine was associated with a
reduced risk of PO-UR. There was moderate-certainty
evidence that avoiding morphine as part of a spinal or
epidural anaesthetic regimen (summary OR 0⋅14, 95 per
cent c.i. 0⋅06 to 0⋅34; I2 = 0 per cent; 3 trials) or adding
μ-opioid antagonists to the anaesthetic (summary OR 0⋅49,
0⋅24 to 1⋅01; I2 = 0 per cent; 2 trials) reduced the number
of patients with PO-UR.
There was high-certainty evidence that the incidence
of PO-UR was lower when the anaesthetic regimen
included an alternative to morphine (clonidine or sufen-
tanil) for postoperative analgesia (summary OR 0⋅02, 95
per cent c.i. 0⋅00 to 0⋅10; I2 = 0 per cent; 2 trials).
There was very low certainty about the effect
of intramuscularly administered morphine compared
with extradural morphine (OR 0⋅69, 95 per cent c.i. 0⋅22
to 2⋅20; 1 trial)60.
Very few studies reported data on secondary outcomes.
Single studies each assessed UTI30, pain45 and duration
of hospital stay31, and found no evidence for a difference
between intervention and control groups.
Non-steroidal anti-inflammatory drugs (2 RCTs, 343
participants) (Fig. 2)
There was moderate-certainty evidence that diclofenac
suppositories reduced PO-UR in patients undergo-
ing haemorrhoidectomy compared with placebo or no
suppository (OR 0⋅25, 95 per cent c.i. 0⋅10 to 0⋅65; 2
trials)43,61. One trial61 assessed pain and found no effect
for diclofenac suppositories on the number of patients
requiring postoperative analgesia (OR 0⋅45, 0⋅19 to 1⋅06).
Type of regional anaesthesia (7 RCTs, 795 participants)
(Fig. 2)
There was high-certainty evidence that the risk of PO-UR
was lower with epidural compared with spinal anaesthesia
(0⋅35, 95 per cent c.i. 0⋅12 to 0⋅99; 1 trial)32, and
that pudendal nerve block was associated with a
lower incidence of PO-UR than spinal anaesthesia
© 2018 The Authors. www.bjsopen.com BJS Open 2019; 3: 11–23
BJS Open published by John Wiley & Sons Ltd on behalf of BJS Society Ltd
Prevention and treatment of postoperative urinary retention 15
Reference Intervention Comparator
0·00119
Reduces PO-UR Increases PO-UR
1 841
Odds ratio Odds ratio
0·13 (0·01, 1·19)
0·32 (0·01, 8·25)
0·14 (0·05, 0·44)
0·09 (0·01, 0·87)
0·14 (0·06, 0·34)
Bupivacaine morphine
Bupivacaine, morphine, neostigmine
Epidural, bupivacaine, morphine
Bupivacaine, morphine
Bupivacaine
Morphine avoidance
El Dahab et al.28
El Dahab et al.28
Evron et al.30
Tomaszewski et al.66
Subtotal (I2=0·0%, P=0·939)
Morphine replacement
Gentili and Bonnet34
Kim et al.45
Subtotal (I2=0·0%, P=0·799)
μ-opioid antagonist
Gallo et al.31
Morphine administration
Petersen et al.60
Zand et al.68
Subtotal (I2=0·0%, P=0·640)
NSAID suppository
Khan et al.43
Placer Galan et al.61
Subtotal (I2=0·0%, P=0·502)
Anaesthesia: unilateral versus bilateral
Ehrenberg and Bucher27
Anaesthesia: epidural versus spinal
Gao et al.32
Anaesthesia: general versus epidural
Evron et al.30
Anaesthesia: local versus epidural
Kau et al.42
Anaesthesia: pudendal nerve block versus spinal
Kim et al.44
Anaesthesia: clonidine versus fentanyl
Kim et al.49
Voelckel et al.67
Subtotal (I2=79·5%, P=0·027)
Bupivacaine, neostigmine
Epidural bupivacaine
Bupivacaine
Morphine in spinal bupivacaine
Morphine in ropivacaine
Clonidine in spinal bupivacaine
Sufentanil in ropivacaine
Morphine
Placebo saline
Low-dose naloxone and morphine
Methylnaltrexone  bromide
ExtraduralIntramuscular
Placebo
No suppository
Diclofenac sodium
Diclofenac
Unilateral spinal
Unilateral spinal
Bilateral spinal
Bilateral spinal
Bupivacaine subarachnoid Bupivacaine epidural
General anaesthesia
Local lidocaine with adrenaline
Pudendal nerve block
Clonidine
Epidural bupivacaine
Epidural lidocaine
Spinal anaesthesia
Fentanyl
0·01 (0·00, 0·13)
0·02 (0·00, 0·38)
0·02 (0·00, 0·10)
0·40 (0·14, 1·20)
0·57 (0·22, 1·52)
0·49 (0·24, 1·01)
0·30 (0·10, 0·85)
0·13 (0·02, 1·08)
0·25 (0·10, 0·65)
0·02 (0·00, 0·40)
0·80 (0·21, 3·00)
0·17 (0·01, 5·27)
0·35 (0·12, 0·99)
0·37 (0·07, 2·02)
0·47 (0·04, 5·37)
0·04 (0·01, 0·09)
0·82 (0·24, 2·84)
0·69 (0·22, 2·20)
Fig. 2 Forest plot comparing anaesthetic modifications for the prevention of postoperative urinary retention. A random-effects model
was used for meta-analysis where appropriate. Odds ratios are shown with 95 per cent confidence intervals. NSAID, non-steroidal
anti-inflammatory drug; PO-UR, postoperative urinary retention.
(OR 0⋅04, 0⋅01 to 0⋅09; 1 trial)44. Moderate-certainty
evidence suggested no difference in the effect of
clonidine compared with fentanyl (OR 0⋅82, 0⋅24 to
2⋅84; 1 trial)49.
There was very low certainty of no difference in the
effect of unilateral compared with bilateral spinal anaes-
thesia (summary OR 0⋅17, 95 per cent c.i. 0⋅01 to 5⋅27;
I2 = 79⋅5 per cent; 2 trials)27,67, of general compared with
epidural anaesthesia (OR 0⋅37, 0⋅07 to 2⋅02; 1 trial)30 and
of local compared with epidural anaesthesia (OR 0⋅47,
0⋅04 to 5⋅37; 1 trial)42.
Some evidence for increased duration of hospital stay
was found when patients received bupivacaine epidu-
rally versus subarachnoid bupivacaine (MD 16⋅08 (95
per cent c.i. 1⋅40 to 30⋅76) hours)32 and when patients
received epidural lidocaine alone versus local lidocaine
plus adrenaline (epinephrine) (MD 2⋅28 (1⋅85 to 2⋅71)
hours)42. No evidence for an effect on UTI was found
when patients received general anaesthesia compared with
epidural anaesthesia. Patients who had a pudendal nerve
block reported lower pain ratings than those who received
spinal anaesthesia (WMD −2⋅50, −3⋅16 to −1⋅84), and
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Reference Intervention Comparator
0·00035
Reduces PO-UR Increases PO-UR
1 2887
Odds ratio Odds ratio
1·40 (0·58, 3·40)
0·16 (0·04, 0·66)
0·03 (0·00, 0·28)
0·24 (0·09, 0·60)
0·15 (0·02, 1·27)
0·23 (0·07, 0·80)
Placebo
Placebo
Placebo
Placebo
Placebo
Tamsulosin
Tamsulosin
Tamsulosin
Tamsulosin
Tamsulosin
Tamsulosin
Akkoc et al.16
Basheer et al.19
Bazzazi et al.20
Madani et al.57
Mohammadi-Fallah et al.58
Subtotal (I2=75·8%, P=0·002)
Phenoxybenzamine
Evron et al.30
Goldman et al.35
Lose and Lindholm55
Subtotal (I2=75·4%, P=0·017)
Prazosin
Cataldo and Senagore26
Alfuzosin
Akkoc et al.16
Tamsulosin versus alfuzosin
Akkoc et al.16
Gönüllü et al.36
Petersen et al.59
Subtotal (I2=16·7%, P=0·301)
Dibenzyline
Livne et al.54
Livne et al.54
Subtotal (I2=0·0%, P=0·801)
Overall (I2=57·6%, P=0·004)
Epidural bupivacaine, morphine
No treatment
Placebo
Epidural bupivacaine, morphine, phenoxybenzamine
Phenoxybenzamine
Phenoxybenzamine
Prazosin
Prazosin
Prazosin
Placebo
Placebo
No treatment
PlaceboAlfuzosin
No treatment (abdominal hysterectomy)
No treatment (vaginal hysterectomy)
Dibenzyline (abdominal hysterectomy)
Dibenzyline (vaginal hysterectomy)
AlfuzosinTamsulosin
0·01 (0·00, 0·10)
0·11 (0·03, 0·43)
0·47 (0·13, 1·70)
0·10 (0·01, 0·69)
0·67 (0·22, 2·07)
0·21 (0·06, 0·79)
0·18 (0·04, 0·87)
0·23 (0·07, 0·70)
0·21 (0·08, 0·52)
0·24 (0·14, 0·41)
0·74 (0·16, 3·44)
0·36 (0·15, 0·86)
0·19 (0·06, 0·59)
0·36 (0·19, 0·69)
Fig. 3 Forest plot comparing alpha-blocker administration for the prevention of postoperative urinary retention. A random-effects
model was used for meta-analysis where appropriate. Odds ratios are shown with 95 per cent confidence intervals. PO-UR,
postoperative urinary retention.
Reference Intervention Comparator
0·0124
Reduces PO-UR Increases PO-UR
1 80·4
Odds ratio Odds ratio
0·13 (0·01, 1·19)
0·32 (0·01, 8·25)
0·25 (0·08, 0·83)
Bupivacaine, morphine
Bupivacaine
Placebo (saline)
Bupivacaine, morphine, neostigmine
Bupivacaine and neostigmine
Distigmine bromide
Urecholine
Drotaverine hydrochloride
Cholinergic
El Dahab et al.28
El Dahab et al.28
Anti-spasmodic
Tomaszewski and Balkota65
Benzodiazepine
Hershberger and Milad39
Cameron24
Bowers et al.21
Subtotal (I2=49·0%, P=0·117)
No urecholine
No treatment
Placebo salineLorazepam
0·42 (0·12, 1·46)
1·67 (0·44, 6·33)
0·45 (0·04, 5·10)
0·29 (0·11, 0·78)
Fig. 4 Forest plot comparing pharmacological interventions for prevention of postoperative urinary retention. A random-effects model
was used for meta-analysis where appropriate. Odds ratios are shown with 95 per cent confidence intervals. PO-UR, postoperative
urinary retention.
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Reference Intervention Comparator
0·00833
Reduces PO-UR Increases PO-UR
1 120
Odds ratio Odds ratio
Bed rest
No treatment
No intraoperative intravenous fluid restriction
Early ambulation
Mobilized in recovery room
Intraoperative intravenous fluid restriction (≤500 ml)
Perioperative intravenous fluid restriction group
Postoperative oral fluids ≤250 ml
Mobilization
Kim et al.46,48
Hansen and Olsen38
Subtotal (I2=0·0%, P=0·679)
Intravenous fluids
Kozol et al.50
Oral fluids
Bailey and Ferguson18
Preoperative ultrasound monitoring
Joelsson-Alm et al.41
Electroacupuncture
Gao et al.33
Bladder stimulator
Butwick et al.23
Postoperative anal packing
Kim et al.47
Straight catheterization in recovery room
Hozack et al.40
Lee et al.52
Subtotal (I2=0·0%, P=0·996)
Hydration group
Free access
No preoperative scanning
No treatment
Placebo
No treatment
No treatment
Catheter if no void and bladder volume >400 ml
Electroacupuncture
Bladder stimulator
Postoperative anal packing
Catheterization in recovery room
0·21 (0·09, 0·45)
0·59 (0·26, 1·34)
0·59 (0·18, 1·88)
0·59 (0·18, 1·89)
0·35 (0·21, 0·57)
0·32 (0·16, 0·63)
0·39 (0·19, 0·80)
0·18 (0·01, 3·93)
1·38 (0·40, 4·80)
0·81 (0·35, 1·92)
1·40 (0·46, 4·22)
0·55 (0·31, 0·98)
Fig. 5 Forest plot comparing non-pharmacological interventions for prevention of postoperative urinary retention. A random-effects
model was used for meta-analysis where appropriate. Odds ratios are shown with 95 per cent confidence intervals. PO-UR,
postoperative urinary retention.
fewer patients required postoperative analgesia (OR 0⋅20,
0⋅10 to 0⋅41)44.
Alpha-blockers (12 RCTs, 1283 participants) (Fig. 3)
There was high-certainty evidence that alpha-blockers
were associated with a lower incidence of PO-UR (sum-
mary OR 0⋅24, 95 per cent c.i. 0⋅14 to 0⋅41; I2 = 57⋅6
per cent; 12 trials). Studies compared tamsulosin (5
trials)16,19,20,57,58, phenoxybenzamine (3)30,35,55, prazosin
(3)26,36,59, alfuzosin (1 trial)16 and dibenzyline (1 trial)54
with placebo or no treatment. Two of the phenoxybenza-
mine trials were restricted to women. All trials of other
alpha-blockers were either restricted to men or did not
report on sex. There were no clear differences in effect
based on type of alpha-blocker or sex. There was moderate
certainty for no evidence of a difference in effect of tam-
sulosin compared with alfuzosin (OR 0⋅74, 0⋅16 to 3⋅44; 1
trial)16.
No evidence for an effect of alpha-blockers was found
on secondary outcomes of UTI (3 studies), pain (2) or
duration of hospital stay (1).
Cholinergic drugs (3 RCTs, 262 participants) (Fig. 4)
There was low certainty about the effect of cholinergic
drugs on PO-UR (summary OR 0⋅42, 95 per cent c.i. 0⋅12
to 1⋅46; I2 = 49⋅0 per cent; 3 trials)21,24,28. Studies compared
urecholine (administered orally) with standard care, intra-
muscular distigmine bromide with saline placebo, and the
addition of neostigmine to the anaesthetic regimen.
Antispasmodic drugs (1 RCT, 201 participants) (Fig. 4)
There was high-certainty evidence for a lower incidence
of PO-UR amongst patients given drotaverine hydrochlo-
ride intramuscularly after spinal anaesthesia compared
with a standard anaesthetic regimen (OR 0⋅29, 95 per cent
c.i. 0⋅11 to 0⋅78; 1 trial)65.
Benzodiazepines (1 RCT, 90 participants) (Fig. 4)
There was low certainty regarding the effect of the benzo-
diazepine lorazepam compared with placebo (OR 0⋅45, 95
per cent c.i. 0⋅04 to 5⋅10; 1 trial)39. This trial found no effect
for lorazepam on pain scores or hospital stay (h) (MD 1⋅00,
0⋅20 to 1⋅80, and MD 0⋅80, −0⋅16 to 1⋅76, respectively).
Non-pharmacological interventions for prevention
of postoperative urinary retention (Tables S5
and S6; Fig. 5)
Early mobilization (2 RCTs, 305 participants)
High-certainty evidence was found for an association
between early mobilization and reduced incidence
© 2018 The Authors. www.bjsopen.com BJS Open 2019; 3: 11–23
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Reference Intervention Comparator
0·00074
Reduces PO-UR Increases PO-UR
1 1359
Odds ratio Odds ratio
Alfusozine
Phenoxybenzamine
Alfusozine
Phenoxybenzamine
Carbachol
Carbachol and diazepam
Bethanachol (no midazolam pretreatment)
Midazolam followed by bethanachol
Hot pack
Gauze soaked in warm water
Gauze soaked in warm water
Caffeine
Posterior tibial nerve stimulation
Infrared radiation
Moxibustion
Moxibustion
Placebo
Placebo
Carbachol and diazepam
Carbachol
Placebo
Placebo
Placebo (no midazolam pretreatment)
Placebo (no midazolam pretreatment)
No treatment
No treatment
Hot pack
Warm water
Sham posterior tibial nerve stimulation
Hot compress
Hot compress
Infrared radiation
Alpha-blocker
Alpha-blocker versus carbachol ± diazepam
Burger et al.22
Burger et al.22
Tammela64
Tammela64
Subtotal (I2=85·6%, P=0·008)
Subtotal (I2=87·4%, P=0·005)
Warm gauze or hot pack
Afazel et al.15
Warm gauze versus hot pack
Afazel et al.15
Caffeine
Leach et al.51
Posterior tibial nerve stimulation
Rardin et al.63
Infrared radiation versus hot compress
Li et al.53
Moxibustion versus hot compress
Li et al.53
Moxibustion versus infrared radiation
Li et al.53
Afazel et al.15
Subtotal (I2=0·0%, P=0·680)
Cholinergic ± benzodiazepines
Tammela64
Burger et al.22
Gottesman et al.37
Gottesman et al.37
0·74 (0·35, 1·58)
0·65 (0·35, 1·21)
0·02 (0·00, 0·54)
0·02 (0·00, 0·36)
0·59 (0·24, 1·46)
0·12 (0·01, 1·20)
0·45 (0·18, 1·09)
0·82 (0·24, 2·84)
0·11 (0·02, 0·61)
0·14 (0·02, 0·75)
0·05 (0·01, 0·31)
0·03 (0·01, 0·18)
0·04 (0·01, 0·14)
1·06 (0·55, 2·02)
0·22 (0·09, 0·53)
0·49 (0·10, 2·33)
0·69 (0·38, 1·25)
0·16 (0·07, 0·39)
0·35 (0·08, 1·44)
Fig. 6 Forest plot comparing pharmacological and non-pharmacological interventions for treatment of postoperative urinary retention
A random-effects model was used for meta-analysis where appropriate. Odds ratios are shown with 95 per cent confidence intervals.
PO-UR, postoperative urinary retention.
of PO-UR (summary OR 0⋅35, 95 per cent c.i. 0⋅21 to 0⋅57;
I2 = 0 per cent; 2 trials)38,46,48. There was no evidence for
an effect of early mobilization on pain (1 trial)38.
Fluid restriction (1 RCT, 496 participants)
Low-certainty evidence suggested a lower incidence
of PO-UR amongst patients restricted to 250ml or less
of oral fluids after surgery compared with patients given
free access to fluids (OR 0⋅21, 95 per cent c.i. 0⋅09 to 0⋅45;
1 trial)18. There was moderate certainty for no evidence
of an effect of intravenous fluid restriction (summary OR
0⋅59, 0⋅26 to 1⋅34; I2 = 0 per cent; 2 trials)50,52.
Other approaches
There was low-certainty evidence of reduced PO-UR
in patients assessed with frequent preoperative ultra-
sound scanning and catheterized when the bladder
volume exceeded 400ml, compared with patients
with no preoperative scanning (OR 0⋅55, 95 per
cent c.i. 0⋅31 to 0⋅98; 1 trial)41. Trials investigating
other non-pharmacological interventions, including
electroacupuncture33, external bladder stimulator23, post-
operative anal packing after haemorrhoidectomy47 and
straight catheterization in the recovery room40, found no
evidence for a reduction in PO-UR.
There was no evidence for an effect of bladder stimul-
ator23 on pain, for preoperative ultrasound monitoring41
or straight catheterization in recovery room40 on UTI, or
for preoperative ultrasound monitoring41 on duration of
hospital stay.
Pharmacological treatment of postoperative
urinary retention (Tables S5 and S6; Fig. 6)
Alpha-blockers (2 RCTs, 543 participants)
There was very low certainty regarding the effect of pheno-
xybenzamine or alfuzosin compared with placebo (sum-
mary OR 0⋅35, 95% CI 0⋅08 to 1⋅44; 2 trials)22,64. The
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same trials provided evidence of very low certainty about
the effect of phenoxybenzamine versus carbachol or alfu-
zosin versus carbachol and diazepam (summary OR 0⋅49,
0⋅10 to 2⋅33).
Benzodiazepines and cholinergic drugs (4 RCTs, 325
participants)
There was no evidence of a reduction in PO-UR among
patients given carbachol, with or without diazepam, com-
pared with placebo (OR 0⋅74, 95 per cent c.i. 0⋅35 to 1⋅58,
and OR 0⋅65, 0⋅35 to 1⋅21)22,64. There was no evidence
for an effect of midazolam, although fewer patients devel-
oped PO-UR when they were subsequently rerandomized
to receive bethanechol (OR 0⋅02, 0⋅00 to 0⋅54, and OR
0⋅02, 0⋅00 to 0⋅36, respectively)37.
Non-pharmacological treatment of postoperative
urinary retention (4 trials) (Tables S5 and S6; Fig. 6)
Interventions for the treatment of urinary retention were
evaluated only in single trials. High-certainty evidence
was found for a beneficial effect of applying a hot pack
or gauze soaked in warm water to the suprapubic region
(OR 0⋅04, 95 per cent c.i. 0⋅01 to 0⋅14; 1 trial)15. The
same trial provided moderate certainty that there was
no difference of effect between the two interventions.
There was also moderate-certainty evidence for reduced
PO-UR amongst patients given posterior tibial nerve stim-
ulation (PTNS) compared with sham PTNS (OR 0⋅45,
0⋅18 to 1⋅09; 1 trial)63. There was low-certainty evidence
that a cup of warm coffee reduced PO-UR compared
with warm water (OR 0⋅12, 0⋅01 to 1⋅20; 1 trial)51, and
for no effect of infrared radiation compared with a hot
compress (OR 0⋅82, 0⋅24 to 2⋅84; 1 trial)53. This trial
also provided moderate-certainty evidence that moxibus-
tion was associated with a lower incidence of PO-UR
compared with either a hot compress or infrared radia-
tion (OR 0⋅11, 0⋅02 to 0⋅61, and OR 0⋅14, 0⋅02 to 0⋅75,
respectively).
Discussion
This systematic review summarizes the effectiveness
of interventions evaluated for the prevention or treat-
ment of PO-UR. The majority of the 48 RCTs evaluated
preventive interventions. Based on GRADE assessments,
there was high-certainty evidence to suggest that the fol-
lowing may help reduce the risk of patients developing
PO-UR after surgery: replacing morphine in the anaes-
thetic regimen; using alpha-blockers or the antispasmodic
drotaverine; early postoperative mobilization; and epidu-
ral anaesthesia or pudendal nerve blocks rather than
spinal anaesthesia. The number of patients who would
need to receive the intervention for one case of urinary
retention to be prevented ranged from 2 (95 per cent
c.i. 2 to 3) for morphine replacement to 9 (7 to 30)
for drotaverine. There was some evidence that avoiding
morphine in the anaesthetic regimen, diclofenac supposi-
tories (NSAID), μ-opioid antagonists, oral fluid restriction
and preoperative ultrasound monitoring were also associ-
ated with a lower risk of PO-UR, but the evidence here
was less certain. The number of patients that would need
to receive these interventions for one case of PO-UR
to be prevented ranged from 4 (4 to 6) for morphine
avoidance to 11 (9 to 25) for NSAIDs. For patients who
developed PO-UR after surgery, there was high-certainty
evidence that a hot pack or gauze soaked in warm water
reduced the need for catheterization, with two patients
needing this treatment to resolve one case of urinary
retention. There was also evidence that moxibustion,
posterior tibial nerve stimulation and caffeinated drinks
could help to treat PO-UR, although the evidence was
less certain.
There was no evidence that the following could help to
reduce the risk of PO-UR: use of an external bladder stim-
ulator, postoperative anal packing (after haemorrhoidec-
tomy), cholinergic drugs, lorazepam (benzodiazepine)
and electroacupuncture, intramuscularly administered
morphine (versus extradural administration), unilateral
anaesthesia (versus bilateral anaesthesia), general or local
anaesthesia (versus epidural anaesthesia) and straight
catheterization in the recovery room. For treatment
of PO-UR, there was no evidence to support the use
of alpha-blockers or cholinergic drugs with or without
benzodiazepines.
This review had a number of strengths and limitations.
Cochrane recommendations for conducting systematic
reviews8 were followed. A highly sensitive search strategy
was developed and performed by an independent infor-
mation specialist, to identify as many relevant studies as
possible and reduce the risk of publication bias. Searches
were not limited by language or publication status. Sup-
plementary internet searches were undertaken to identify
grey literature, including ongoing and completed clinical
trials. However, it was not possible to contact study authors
to request unavailable data. In addition, owing to resource
limitations, it was not possible to translate studies where
reviewers were unable to identify whether the study fully
met the inclusion criteria. Although one study53 evaluating
the effects of moxibustion and infrared radiation was
identified, the search did not include Chinese databases in
which studies of similar interventions are more likely to
be reported. A review of studies evaluating moxibustion as
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an intervention for treating PO-UR69 included 19 studies
identified from Chinese sources; these were not targeted
in the search strategy due to difficulties in accessing and
interpreting this evidence.
To minimize bias and errors, all stages of the review were
performed independently by two reviewers, including
a public contributor who had experienced PO-UR. All
included RCTs were assessed using the new Cochrane
risk-of-bias 2.0 tool10,11. This identified a number of
methodological weaknesses in the included trials, partic-
ularly in relation to methods of treatment allocation and
blinding of participants and study personnel. GRADE14
was used to assess the quality of the overall body of evi-
dence. This allowed for systematic and transparent ratings
summarizing the quality of evidence for each intervention
evaluated, taking into account both the strength of the asso-
ciation (magnitude of effect and precision) and the risk of
bias in the included studies, inconsistency (heterogeneity),
publication bias and applicability to the research question.
Reasons for downgrading evidence, where appropriate, are
shown in Table S5 (supporting information).
There were a number of limitations in the reviewed
studies. A wide variety of definitions for urinary reten-
tion were used. Although the majority of trials defined
PO-UR by the need for a urinary catheter, catheterization
protocols varied between studies. Catheter use can be con-
sidered a strong proxy measure of PO-UR, but for studies
where it was not stated explicitly that catheterization was
performed as treatment for urinary retention, it must be
noted that there could be other reasons for catheterization,
including postoperative fluid balance monitoring or poor
mobility70. The surgical population varied across studies,
as did surgical and anaesthetic techniques. Included studies
assessed a wide range of interventions, and analyses were
stratified based on the aim (prevention or treatment), type
(pharmacological or non-pharmacological) and category
of intervention. Very few studies evaluated the same inter-
ventions: usually a maximum of three per comparison.
The only comparisons involving a large number of studies
were related to alpha-blockers, which were evaluated in
12 trials. Within this category, several different types of
alpha-blocker were evaluated, with a maximum of five
studies evaluating the same intervention. Thus there were
insufficient data to conduct a sensitivity analysis, which
would have provided information on whether the effective-
ness of interventions varied based on factors such as sex,
type of surgery, intervention dose, ethnicity or risk of bias.
Most were two-arm trials with a placebo or control group
(no treatment), but some studies included active com-
parisons and multiple groups comparing more than one
category of intervention. This resulted in a wide variety
of comparisons, some consisting of single studies. Studies
assessing interventions of the same category often differed
in the method or timing of administration. This resulted in
considerable heterogeneity amongst the included studies
and meta-analysis was inappropriate.Where heterogeneity
was present in a meta-analysis, GRADE assessments were
downgraded to reflect reduced certainty in the evidence.
Themost common reason for downgrading was confidence
intervals that included the null, followed by risk of bias.
There are two existing reviews related to PO-UR. A
Cochrane systematic review71 evaluated drugs for the
treatment of urinary retention after surgery. This review71
identified seven studies evaluating the effect of cholin-
ergic agents, alpha-blockers, sedatives and prostaglandin
(alone or in combinations) on PO-UR. Three of the
studies did not meet the inclusion criteria for the present
review: one measured PO-UR on postoperative day nine,
72 h after catheter removal, and two were conducted in
populations of women with stress urinary incontinence.
The review concluded that there was ‘little trial-based
evidence that could shed light on the effectiveness or oth-
erwise of alpha-blockers or sedatives in the treatment of
post-operative urinary retention’. This is consistent with
the findings of the present review with regard to treat-
ment of PO-UR. The other review article72 was restricted
to trials of alpha-blockers for prevention of PO-UR. It
included 15 RCTs and reported a significantly reduced
risk of PO-UR, consistent with the findings of the present
review. There are also two published Cochrane protocols
which are yet to be completed, one aimed at reviewing the
evidence on drugs for the prevention of PO-UR (2013)73
and the other on non-drug treatments for PO-UR (2015)6.
Large, robust and well designed RCTs are needed to
confirm the effects of the interventions studied in this
review, and to inform the design of an effective preven-
tion and treatment protocol for surgical patients at risk
of developing PO-UR. Trials should follow CONSORT
reporting standards74 to ensure appropriate methods for
minimizing risk of bias, along with the perspectives of
patients and economic evaluation.
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